- Primary safety and feasibility endpoints achieved - Preliminary positive signs of antitumoral effect in all evaluable patients- Company preparing now registration clinical plan, including EU and USA

Paris, France, Cambridge, MA, Jul 7, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine...